Skip to main content

A Brief Review on Sustained Release Matrix Tablets of Baclofen

Pharma courses

pharma courses

Magazine Home


PharmaTutor (December- 2014)


ISSN: 2347 - 7881
(Volume 2, Issue 12)


Received On: 22/10/2014; Accepted On: 28/10/2014; Published On: 01/12/2014


AUTHORS: Singh Surya Pratap*, Soni Shankar Lal, Khinchi Mahaveer Prasad, Gulia Ritu, Namdev Abhisek
Department of pharmaceutics, Kota College of  Pharmacy,
Ranpur, Kota, Rajasthan, India


The objective of the present study was to focus on sustained release matrix tablets of baclofen, for treatment of spastically resulting from multiple sclerosis, flexor spasm and muscular rigidity. Designing effective therapies for Spinal cord injury (SCI) has been a challenging problem because spinal cord injuries are heterogeneous in causality, severity and location of injury.

Effective drug therapy for Spinal cord injury (SCI) first became a reality in 1990 with the finding that the steroid drug methylprednisolone(MP) can significantly improve recovery. Significant advances in recent year, including an effective drug therapy for acute SCI, have improve recovery. In spinal cord injury, pain persist for longer period i.e., several months, hence the long-term treatment is necessary for maintaining the drug concentration in the therapeutic range.

Hence, there is a need of sustained release dosage form. Baclofen,4-amino-3-(4-chlorophenyl)-butyric acid is another structural analog of GABA, which is widely used now a days in the treatment of multiple sclerosis, flexor spasms, muscular rigidity. spinal cord injuries and other spinal cord diseases.


How to cite this article: SP Singh, SS Lal, KM Prasad, R Gulia, N Abhisek; A Brief Review on Sustained Release Matrix Tablets of Baclofen; PharmaTutor; 2014; 2(12); 86-98